** Shares of Artrya fall as much 9% to A$0.455, their lowest level since Oct 23
** The medical technology co receives firm commitments to raise A$5 mln ($3.29 mln) via placement
** Issue price of A$0.42 represents 16% discount to co's last close on Thursday, Nov. 7
** Adds, fund raised to be allocated to product development, others, as co awaits FDA clearance on its patented Salix Coronary Anatomy product
** Stock up 95.8% this year, including session's moves
($1 = 1.5221 Australian dollars)
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。